Armo Biosciences raises about $128 mln for IPO
Redwood City, California-based Armo BioSciences Inc, a late-stage immuno-oncology company has raised about $128 million for its IPO after pricing its over 7.5 million shares at $17 per share. The stock began trading January 26, 2018 on the NASDAQ under the ticker symbol "ARMO." Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp are the lead underwriters. Armo’s pre-IPO backers were Qiming Venture Partners, Decheng Capital, Sequoia Capital, Quan Capital, RTW Investments, Kleiner Perkins Caufield and Byers, OrbiMed, DAG Ventures, NanoDimension, HBM Healthcare Investments and GV.
29 January 2018•3 mins read
